Zemplar

Zemplar (Paricalcitol) is a vitamin D analog prescribed to manage secondary hyperparathyroidism in chronic kidney disease. This oral medication helps regulate calcium and phosphate levels. Suitable for patients requiring vitamin D receptor activation therapy. Short-term use under medical supervision is typical for this EU-manufactured treatment.

Paricalcitol is primarily used to treat secondary hyperparathyroidism in adults with chronic kidney disease undergoing dialysis. It works by reducing elevated parathyroid hormone levels, which helps maintain healthy bone metabolism. Patients with kidney-related calcium imbalances may benefit from this vitamin D analog. It is not intended for general vitamin D deficiency or unrelated conditions.

Common effects of Paricalcitol include mild gastrointestinal discomfort such as nausea or vomiting. Some patients may experience dizziness or headache shortly after taking the medication. These effects are usually temporary and tend to diminish as the body adjusts. Regular monitoring is advised to assess individual tolerance.

Store Paricalcitol at room temperature away from moisture and direct light. Keep this medication out of reach of children and pets. Avoid crushing or splitting capsules unless directed by a healthcare professional. Report any persistent side effects or unusual symptoms to a medical provider promptly.

Paricalcitol may interact with other vitamin D supplements, calcium-based medications, or phosphate binders. Caution is advised when combining with CYP3A4 inhibitors, as they can alter drug metabolism. Alcohol and grapefruit products may also affect how Paricalcitol works. Always inform your doctor about all medications and supplements being taken.